M&T Bank Corp Has $50.03 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

M&T Bank Corp trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 884,513 shares of the biopharmaceutical company's stock after selling 16,834 shares during the period. M&T Bank Corp's holdings in Bristol-Myers Squibb were worth $50,028,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Atria Investments Inc increased its position in Bristol-Myers Squibb by 43.2% during the 4th quarter. Atria Investments Inc now owns 183,154 shares of the biopharmaceutical company's stock valued at $10,359,000 after purchasing an additional 55,296 shares during the period. Assetmark Inc. increased its stake in Bristol-Myers Squibb by 30.7% during the 4th quarter. Assetmark Inc. now owns 259,621 shares of the biopharmaceutical company's stock valued at $14,684,000 after purchasing an additional 60,954 shares in the last quarter. Souders Financial Advisors raised its holdings in shares of Bristol-Myers Squibb by 9.6% in the 4th quarter. Souders Financial Advisors now owns 6,362 shares of the biopharmaceutical company's stock worth $360,000 after acquiring an additional 558 shares during the last quarter. Wealth Advisory Solutions LLC boosted its position in shares of Bristol-Myers Squibb by 4.4% during the fourth quarter. Wealth Advisory Solutions LLC now owns 6,708 shares of the biopharmaceutical company's stock valued at $379,000 after buying an additional 284 shares during the last quarter. Finally, Exencial Wealth Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 8.8% in the 4th quarter. Exencial Wealth Advisors LLC now owns 16,776 shares of the biopharmaceutical company's stock worth $949,000 after acquiring an additional 1,353 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Up 0.7 %

BMY stock traded up $0.41 during midday trading on Wednesday, reaching $59.85. 9,706,344 shares of the company were exchanged, compared to its average volume of 11,271,845. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The company has a market cap of $121.44 billion, a price-to-earnings ratio of -13.54, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock's 50-day simple moving average is $57.28 and its 200 day simple moving average is $54.97.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.14%. Bristol-Myers Squibb's dividend payout ratio (DPR) is -56.11%.

Analyst Ratings Changes

Several analysts have commented on BMY shares. Cantor Fitzgerald lifted their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Morgan Stanley lifted their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a report on Tuesday, November 12th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday, November 13th. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and an average target price of $57.86.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.